Immunogenicity of biological therapeutics: from assay to patient

被引：61
作者：
Krieckaert, Charlotte [1 ]
Rispens, Theo [2 ]
Wolbink, Gertjan [1 ,2 ]
机构：
[1] Sanquin Res, Jan Van Breemen Res Inst Reade, NL-1056 AB Amsterdam, Netherlands
[2] Sanquin Res, Dept Immunopathol, NL-1056 AB Amsterdam, Netherlands
来源：
CURRENT OPINION IN RHEUMATOLOGY | 2012年 / 24卷 / 03期
关键词：
assay techniques; biological therapies; clinical implications; immunogenicity; therapeutic drug monitoring; RHEUMATOID-ARTHRITIS PATIENTS; ANTI-ADALIMUMAB ANTIBODIES; HUMAN IGG4; INFLIXIMAB; SERUM; INTERFERENCE; ASSOCIATION; ETANERCEPT; EFFICACY; THERAPY;
D O I：
10.1097/BOR.0b013e3283521c4e
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of review To give an overview of the current knowledge on assay techniques and clinical implications of immunogenicity of biological therapeutics. Recent findings Assay techniques for the measurement of immunogenicity have improved, expanding the understanding of the immune response against biological therapeutics. Knowledge on the clinical effect of immunogenicity enables the treatment of patients in a targeted fashion, as a step towards personalized medicine. Summary Biological medications are able to induce an antidrug immune response. Immunogenicity impairs clinical response and is associated with adverse events. Several confounding factors influence the measurement of immunogenicity, including drug interference and background problems. Concomitant administration of methotrexate lowers the frequency and amount of antibodies formed, whereby the efficacy of biologicals is improved. Algorithms for therapeutic drug monitoring could aid in adapting treatment strategies in a controlled setting.
引用
收藏
页码：306 / 311
页数：6
相关论文
共 34 条
[1]   Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease [J].
Afif, Waqqas ;
Loftus, Edward V., Jr. ;
Faubion, William A. ;
Kane, Sunanda V. ;
Bruining, David H. ;
Hanson, Karen A. ;
Sandborn, William J. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) :1133-1139
[2]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[3]   Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study [J].
Bartelds, G. M. ;
Wijbrandts, C. A. ;
Nurmohamed, M. T. ;
Stapel, S. ;
Lems, W. F. ;
Aarden, L. ;
Dijkmans, B. A. C. ;
Tak, P. P. ;
Wolbink, G. J. .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (05) :817-821
[4]   Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms [J].
Bartelds, G. M. ;
Wijbrandts, C. A. ;
Nurmohamed, M. T. ;
Wolbink, G. J. ;
de Vries, N. ;
Tak, P. P. ;
Dijkmans, B. A. C. ;
Crusius, J. B. A. ;
van der Horst-Bruinsma, I. E. .
ARTHRITIS AND RHEUMATISM, 2009, 60 (08) :2541-2542
[5]   Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up [J].
Bartelds, Geertje M. ;
Krieckaert, Charlotte L. M. ;
Nurmohamed, Michael T. ;
van Schouwenburg, Pauline A. ;
Lems, Willem F. ;
Twisk, Jos W. R. ;
Dijkmans, A. C. ;
Aarden, Lucien ;
Wolbink, Gerrit Jan .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (14) :1460-1468
[6]   Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study [J].
Bartelds, Geertje M. ;
de Groot, Els ;
Nurmohamed, Michael T. ;
Hart, Margreet H. L. ;
van Eede, Peter H. ;
Wijbrandts, Carla A. ;
Crusius, Jakob B. A. ;
Dijkmans, Ben A. C. ;
Tak, Paul Peter ;
Aarden, Lucien ;
Wolbink, Gerrit J. .
ARTHRITIS RESEARCH & THERAPY, 2010, 12 (06)
[7]   Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab [J].
Bendtzen, Klaus ;
Geborek, Pierre ;
Svenson, Morten ;
Larsson, Lotta ;
Kapetanovic, Meliha C. ;
Saxne, Tore .
ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3782-3789
[8]   Is There a Need for Immunopharmacologic Guidance of Anti-Tumor Necrosis Factor Therapies? [J].
Bendtzen, Klaus .
ARTHRITIS AND RHEUMATISM, 2011, 63 (04) :867-870
[9]   Pure red-cell aplasia and epoetin therapy [J].
Bennett, CL ;
Luminari, S ;
Nissenson, AR ;
Tallman, MS ;
Klinge, SA ;
McWilliams, N ;
McKoy, JM ;
Kim, B ;
Lyons, EA ;
Trifilio, SM ;
Raisch, DW ;
Evens, AM ;
Kuzel, TM ;
Schumock, GT ;
Belknap, SM ;
Locatelli, F ;
Rossert, J ;
Casadevall, N .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (14) :1403-1408
[10]   Frequency and Effectiveness of Dose Increase of Adalimumab, Etanercept, and Infliximab in Daily Clinical Practice [J].
Blom, M. ;
Kievit, W. ;
Kuper, H. H. ;
Jansen, T. L. ;
Visser, H. ;
den Broeder, A. A. ;
Brus, H. L. M. ;
van de laar, M. A. F. J. ;
van Riel, P. L. C. M. .
ARTHRITIS CARE & RESEARCH, 2010, 62 (09) :1335-1341
1234